By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancerselective strategy for treatment of p53-deficient tumors.
Introduction
By inhibiting dynamics of microtubules, microtubuleactive drugs (paclitaxel, docetaxel, vincristine, vinblastine) , cause mitotic arrest leading to cell death (Rowinsky and Donehower, 1995; Jordan and Wilson, 1998) . Inhibition of mitotic progression is equally toxic for proliferating normal and cancer cells. Resting cells may survive exposure to microtubule-active drugs (Blagosklonny and Pardee, 2001 ). Furthermore, paclitaxel-induced p53 prevents mitotic arrest thus decreasing paclitaxel-mediated cytotoxicity in A549 cells (Torres and Horwitz, 1998; Giannakakou et al., 2001) . Loss of wt p53, one of the most common alterations in human cancer, could be exploited to discriminate between p53-deficient cancer cells and normal cells (Kastan et al., 1995) . Following DNA damage, wt p53 transactivates p21 and other genes, causing G1 and G2 arrest . For example, sublethal DNA damage causes G2 arrest in wt p53-proficient HCT116 cells and prevents their entry into mitosis (Bunz et al., 1998) . HCT116 cells with knockout of either p53 or p21 enter mitosis despite pretreatment with doxorubicin, a DNA damaging drug. This slight difference allowed one to prevent PTX-induced cell death of parental cells with wt p53 while killing checkpoint-deficient cells . The strategy has been proposed to selectively kill p53-deficient cancer cells.
However, a G2 checkpoint can be activated by parallel pathways (Passalaris et al., 1999; Chan et al., 2000) including DNA damage-independent pathways (Smith et al., 2002) , and some p53-deficient cells might be arrested in G2. Then, induction of G2 arrest by low levels of DNA damage may protect some cancer cells with mutant p53 from PTX-mediated death. While activation of wt p53-dependent checkpoint is the basis for protection of normal cells, abrogation of a p53 independent checkpoint may be needed in order to avoid undesirable protection of p53-deficient cancer cells. Can we selectively manipulate G2 checkpoints by activating p53-dependent and inactivating p53-independent pathways?
Starting with caffeine which uncouples S phase from mitosis and abrogates G2 arrest (Lau and Pardee, 1982) , several compounds that abrogate a p53-independent G2 checkpoint have been identified. Thus, UCN-01 prevents G2 arrest in cells lacking p53 (Yu et al., 1998; Busby et al., 2000) . It has been demonstrated that UCN-01 inhibits Chk1, and this inhibition occurs at low concentrations of UCN-01 (Graves et al., 2000; Hu et al., 2001) . Chk 1 and Cdc25C-associated protein kinase 1 (cTAK1) are inhibited by UCN-01 with IC50s of 11 and 27 nM, respectively, leading to abrogation of G2 arrest (Busby et al., 2000) . In contrast, the Chk 2 kinase is 100-fold more resistant to inhibition by UCN-01 (IC 50 , 1040 nM). Thus in theory, pharmacological tools to activate and to inactivate G2 checkpoints are available. But is it achievable? In other words, can we select concentrations and sequences of modulators of G2 to manipulate the toxicity of PTX?
The present study does not utilize either DNA damaging agents or UCN-01 to kill cells. Pretreatment with low concentrations of DNA damaging drugs is intended to activate a p53-dependent checkpoint. It is essential to avoid G2 arrest of p53-deficient cancer cells. Post-treatment with low concentrations of UCN-01 is intended to release those p53-deficient cancer cells being arrested in G2 via a p53-independent pathway. Paclitaxel is intended for the final mission: killing the released checkpoint-incompetent cells.
Results

Doxorubicin protects HL60 cells against PTX
Using parental cells and clones lacking either p53 or p21, it has been demonstrated that pretreatment with low concentrations of doxorubicin selectively protects cells with the p53/p21 pathway against paclitaxel (PTX). This leads to the notion that p53-deficient cells could be selectively killed by this simple sequence of two drugs . However, it has been noticed that the same sequence antagonized killing of HL60 and Jurkat cells, lacking wt p53 (Blagosklonny, 1999; Blagosklonny et al., 2002) . As shown in Figure 1a , pretreatment with low concentrations (ranging from 5 -50 ng/ml) of doxorubicin (DOX), protected HL60 cells against the cytotoxicity of PTX (closed circles). Higher concentrations (100 -200 ng/ml) of DOX were too cytotoxic by themselves ( Figure 1a : open circles) to prevent PTX-mediated death. Therefore at higher concentrations of DOX, killing curves with and without PTX coincided, indicating that DOX rather than PTX caused cell death. Therefore, concentrations of DOX 20 -50 ng/ml were chosen for further experiments. Other DNA damaging drugs including actinomycin D (1 -10 ng/ ml), etoposide (100 -400 ng/ml), cisplatin (1 mM) and topotecan (10 ng/ml) were also protective against PTX.
Choosing UCN-01 concentrations
Protection of HL60 cells reveals the limitation of the DOX-PTX sequence for potential therapy of p53-deficient tumors. It has been shown that UCN-01 can abrogate p53-independent G2 arrest. Would it restore the cytotoxicity caused by PTX? First, concentrations of UCN-01 that override the protective effects of DOX were determined. As shown in Figure 1b Similar results were obtained with Jurkat, another p53-deficient cell line (Figure 2a ). In the absence of UCN-01 (0), pretreatment with DOX protected cells against PTX. UCN-01 abolished this protection and restored cell killing (Figure 2a ).
Post-treatment with UCN-01 did not abrogate p53-dependent checkpoint
It is important to ensure that UCN-01 does not abrogate the p53-dependent checkpoint. Previous publications have clearly demonstrated that DNA damage-induced G2 arrest of HCT116 cells solely depends on a p53-dependent checkpoint (Bunz et al., 
1998
; Blagosklonny et al., 2000) . Therefore, HCT116 cells were used in this study as cells possessing p53-dependent but lacking p53-independent checkpoints. By inducing p21, DOX causes G2 arrest in HCT116 cells (Chang et al., 1999; Blagosklonny et al., 2000) . Thus, post-treatment with UCN-01 did not override p21 induction caused by DOX. Consistently, posttreatment with 25 nM UCN-01 did not abrogate DOXmediated cytoprotection of HCT116 cells (Figure 2b ).
In agreement with previous results , pretreatment with DOX did not protect HCT-p217/7, p21-knockout HCT116 cells ( Figure  2c ). In these cells lacking G2 checkpoints, 25 nM UCN-01 did not increase the cytotoxicity of PTX, demonstrating that (at indicated concentrations) UCN-01 cytotoxicity is checkpoint-related (Figure 2c ).
Abrogation of G2 checkpoint leads to apoptosis in DOXpretreated Jurkat and HL60 cells
Then, the effects of UCN-01 on PTX-induced cell death were investigated in detail. As expected, PTX induced 4N arrest, as determined by flow cytometry (Figure 3a : PTX). This arrest was accompanied by Raf-1 and Bcl-2 phosphorylation (two bands on Figure 2 Comparison of cells with different defects in G2 checkpoints. Cells were preincubated overnight with 40 ng/ml DOX. Unless indicated 'no PTX', 100 nM PTX was added to cells, either with 12, 25, 50, 100 nM UCN-01 or without UCN-01 (0). After 2 days, MTT assay was performed as described in Materials and methods. (a) Jurkat (a p53-independent checkpoint), (b) HCT116 (a p53-dependent checkpoint), and (c) HCT p217/7 (no G2 checkpoints) Immunoblot analysis. Cells were treated as described in (a). Immunoblot for apoptotic markers (Caspase-3 and PARP cleavage) and mitotic markers (Raf-1 and Bcl-2 band shift) were performed as described in Materials and methods. (c) After 2 days, MTT assay was performed as described in Materials and methods immunoblot), as markers of mitotic arrest (Blagosklonny, 2001 ). In turn, Raf-1 and Bcl-2 phosphorylation was accompanied by caspase-3 and PARP cleavage, as markers of apoptosis (Figure 3b ), followed by cell death (Figure 3c ). UCN-01 alone slowed down G1 progression (Figure 3a , UCN-01) but did not induce either apoptosis (Figure 3b ) or cell death (Figure 3c) . Furthermore, UCN-01 did not affect either PTXmediated G2/M arrest (Figure 3a, PTX+UCN-01 ), Bcl-2/Raf-1 phosphorylation, PARP and caspase-3 cleavage (Figure 3b ) or cell death (Figure 3c ). DOX alone caused G2 arrest (Figure 3a, DOX) . Pretreatment with DOX prevented PTX-mediated mitotic arrest, because a cell arrested at G2 cannot be simultaneously arrested at mitosis. Therefore, DOX prevented PTX-mediated Raf-1 and Bcl-2 phosphorylation, caspase-3 and PARP cleavage (Figure 3b) , and cell death (Figure 3c) .
Addition of UCN-01 to PTX restored the ability of PTX to cause Raf-1/Bcl-2 phosphorylation, PARP and caspase-3 cleavage (Figure 3b ). Whereas the sequence DOX+PTX was not cytotoxic when compared with PTX alone, the combination DOX+(PTX+UCN-01) was even more cytotoxic than PTX (Figure 3a,c) .
Discussion
In theory, selective killing of cancer cells might be achieved by pharmacologically targeting cancer-specific molecules. Mitotic microtubules, the primary target of microtubule-active drugs such as paclitaxel (PTX), are not specific for cancer cells. Yet, by manipulating cell cycle checkpoints, the selectivity in killing by paclitaxel can be achieved (Li et al., 1999) . By inducing p53-dependent G2 arrest, pretreatment with DOX, a DNA damaging drug, discriminates checkpoint-deficient cells. This strategy may allow one to increase selectivity in killing cancer cells with mutant p53 .
However, DOX still arrests certain tumor cells lacking wt p53, thus protecting such p53-negative tumor cells against PTX (Blagosklonny, 1999) . For example, low concentrations of DOX (5 -50 ng/ml) arrested Jurkat and HL60 cells at G2, preventing their killing by PTX (Figure 4a) .
The goal of the work was to overcome this obstacle (Figure 4b) . In Jurkat and HL60 cells, the p53/Rb pathway is not involved in the G2 arrest caused by low concentrations of DOX. Most importantly, UCN-01 can override G2 arrest caused by low concentrations of DOX in p53-deficient cells. In other words, abrogation of the p53-independent checkpoint releases cells lacking p53 from G2 arrest. Whereas DOX induces G2 arrest, UCN-01 induces G1 arrest. Noteworthy, G1 progression depends on events occurring in G2 (Sherr, 2002) . As shown here, low concentrations of UCN-01 literally transfer DOX-pretreated wt p53-deficient cells from G2 to G1. The completion of this transition requires mitosis. Once they entered mitosis, cells were killed by PTX.
This strategy is fundamentally different from the combining of drugs to achieve synergistic cytotoxicity. The proposed therapeutic combination is intended to increase the selectivity, not the cytotoxicity of chemotherapy. Here, both DOX and UCN-01 were used at low and nontoxic concentrations. They were utilized not to kill a cell, but to allow PTX to kill a p53-deficient cell. This rational sequence of agents that induces p53-dependent (by DOX) and abrogates p53-independent (by UCN-01) arrest is intended to decrease side effects of PTX without diminishing its therapeutic potential. Importantly, all these drugs either are currently used in cancer therapy (DOX, PTX) or are undergoing clinical trials (UCN-01). Pretreatment with low doses of DOX, followed by By inhibiting Chk1, UCN-01 releases p53-deficient cells into mitosis to be killed by PTX therapeutic doses of microtubule-active agents (e.g. PTX) which are combined with low doses of UCN-01 might be effective in a wide range of p53-deficient tumors, even those that arrest growth by DOX. One foreseen problem is that a useful range of concentrations of DOX and UCN-01 (that can modulate G2 checkpoints without killing cells) is narrow. Given that these compounds were intentionally developed to kill cells, this is not surprising. Therefore, a search for less toxic agents that inhibit the p53-independent checkpoint and induce the p53-dependent checkpoint is warranted.
Materials and methods
Cell lines and therapeutic agents
HL60 and Jurkat, human leukemia cell lines, were obtained from the American Type Culture Collection (Manassas, VA, USA). The human colon cancer cell line HCT116, and clones lacking p21 (HCT-p217/7), generated from HCT116 cells (Waldman et al., 1996) were kindly provided by Bert Vogelstein (John Hopkins University, Baltimore, USA). Paclitaxel (Taxol), was a Bristol-Myers product. Adriamycin (doxorubicin) was obtained from Sigma (St. Louis, MO, USA) and dissolved in DMSO as a 2 mg/ml stock solution. UCN-01 (7-hydroxy-staurosporine) was obtained from the Development Therapeutics Program, NCI, NIH, USA.
Immunoblot analysis
Cells were lysed and soluble proteins were harvested in TNES buffer (50 mM TrisHCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1% (v/v) NP40) containing protease inhibitors (20 mg/ml aprotinin, 20 mg/ ml leupeptin, 1 mM PMSF). Proteins were resolved with either SDS -PAGE as previously described or NuPAGE 4 -12% Bis-Tris gel with MOPS running buffer (NOVEX, San Diego, CA, USA) according to the manufacturer's instructions. Immunoblotting for PARP was performed using rabbit polyclonal antihuman PARP (Upstate Biotechnology, Lake Placid, NY, USA), caspase-3, anti-Raf-1 rabbit polyclonal (C12, Santa Cruz) and antihuman Bcl-2 monoclonal (DAKO) antibodies. Immunoblot was performed using the following antibodies: rabbit polyclonal antihuman PARP (Upstate Biotechnology), mouse monoclonal antihuman caspase-3 (Transduction Lab., Lexington, KY, USA), mouse monoclonal antihuman phospho-Rb (Ser 612, Oncogene Sci), mouse monoclonal antihuman Bcl-2 (DAKO) and rabbit polyclonal antihuman Raf-1 (C12, Santa Cruz, CA, USA).
MTT assay
A total of 15 000 floating (HL60 and Jurkat) or 2500 -5000 attached cells (HCT116, HCT-p217/7) were plated in 0.1 ml in 96-well flat bottom plates and then exposed to the tested agents (final volume 0.2 ml per well). At the indicated time, 20 ml of 5 mg/ml a MTT solution in PBS was added to each well for 2 h. The medium was discarded, 170 ml of DMSO was added to each well to dissolve the formazan crystals. The absorbence at 540 nM was determined using a Biokinetics plate reader (Bio-Tek Instruments, Inc, Winooski, VT, USA). Triplicate wells were assayed for each condition and standard deviations were determined.
Number of dead and live cells
Cells were treated with drugs, and after the indicated time, cells were incubated with Trypan blue and the numbers of blue (dead) cells and transparent (live) cells were counted in a hemocytometer.
Cell cycle analysis
Cell cycle analysis was performed as described previously .
Mitotic index
Cells were incubated with drugs for the indicated time. Cells were washed with PBS, pelleted onto glass slides in a cytocentrifuge, fixed with 90% ethanol with 10% glacial acid and stained with DAPI as described previously . Nuclei were visualized under UV microscopy.
